Phase II trial of docetaxel combined with nedaplatin for patients with recurrent and metastatic nasopharyngeal carcinoma

Purpose: This Phase II trial was designed to evaluate the efficacy and safety of docetaxel combined with nedaplatin as first-line treatment for patients with recurrent or metastatic nasopharyngeal carcinoma.

Methods: In this multicenter Phase II trial, the patients were treated with intravenous docetaxel (75 mg/m², day 1) and nedaplatin (80 mg/m², day 1), each cycle repeated every 3 weeks for two cycles at least.

Results: From January 2010 to November 2013, a total of 78 patients were recruited in this trial. Among them, 73 patients were assessable for response. The treatment was well tolerated. The main hematological adverse event was neutropenia. A total of 12 patients (15.4%) had grade 3 or grade 4 neutropenia. Grade 3 anemia was observed in six patients (7.7%) and no grade 3/4 thrombocytopenia was observed. No Grade 3/4 non-hematological toxicity was observed. There were five complete response (6.8%), 43 partial responses (58.9%), and the overall response rate was 65.8% (95% confidence interval [CI], 48.7%–81.2%). With a median follow-up period of 18.6 months, the median time to progression was 7.9 months (95% CI, 4.2–10.8 months), median overall survival was 15.7 months (95% CI, 11.6–18.5 months).

Conclusion: Docetaxel combined with nedaplatin offers a satisfactory clinical activity and an acceptable safety profile as first-line chemotherapy for patients with recurrent and metastatic nasopharyngeal carcinoma.

Keywords: docetaxel, nedaplatin, nasopharyngeal carcinoma

Introduction
Nasopharyngeal carcinoma (NPC) is prevalent in South China, particularly in Guangdong Province.1,2 Although many improvements in technology and equipment of radiotherapy have been achieved and concurrent chemoradiotherapy was used, the outcome of patients with locoregionally advanced NPC is still unsatisfactory. The main reason of failure is locoregional relapse and distant metastasis.3,4 The NPC is also sensitive to chemotherapy and treatment result of survival prolongation can often be achieved for recurrent and/or metastatic disease. Cisplatin-based chemotherapy regimens are often considered as standard chemotherapy for recurrent or metastatic NPC.5–7 However, gastrointestinal (GI) and renal toxicities are frequent with cisplatin-based regimens. Therefore, new active regimens with a favorable toxicity profile need to be explored.

Docetaxel has shown significant activity against head and neck cancer including NPC. As a single agent, docetaxel is effective in the patients with disseminated NPC who were refractory to platinum-based chemotherapy.8 In addition, a clinical study has indicated that docetaxel plus cisplatin is active as first-line chemotherapy in the patients with metastatic NPC.9 Nedaplatin is a second-generation platinum derivative,
which has similar antitumor activity to cisplatin with less nephrotoxicity and GI toxicity. 10–12 Also, our recent Phase II study of nedaplatin plus capcitabine has shown satisfactory antitumor activity as a salvage chemotherapy for cisplatin-refractory recurrent and metastatic NPC. 13

Based on these promising results, we designed a multicenter, open-label, single-arm Phase II trial to evaluate the efficacy and toxicity of docetaxel plus nedaplatin as first-line chemotherapy for the patients with recurrent or metastatic NPC.

**Patients and methods**

**Patients’ eligibility**

Eligibility criteria included histologically confirmed recurrent and/or metastatic NPC, age from 18 to 75 years, Eastern Cooperative Oncology Group (ECOG) performance status of zero to two, a life expectancy ≥12 weeks, and at least one measurable lesion according to the RECIST (response evaluation criteria in solid tumor) version 1.0 (nasopharyngeal tumor was considered as measurable disease, and the metastatic bone diseases were considered as unmeasurable lesions). Earlier treatment of chemotherapy for advanced disease was not permitted. However, adjuvant, neoadjuvant, or concurrent treatments were permitted, provided that the chemotherapy was completed at least 6 months earlier at the start of this trial. Adequate liver (bilirubin level ≤1.5 mg/dL, aspartate aminotransferase or alanine aminotransferase levels ≤2.5 times the upper limit of normal), renal (serum creatinine level ≤1.5 mg/dL), and bone marrow function (hemoglobin level ≥10 g/dL, white blood cell count ≥4,000/µL, neutrophil count ≥1,500/µL, and platelet count ≥100,000/µL) were required. Written, informed consent was obtained before enrollment, and the study was approved by the local ethical committees from the Fifth Affiliated Hospital of Sun-Yat-Sen University, Cancer Center of Sun-Yat-Sen University, and the People’s Hospital of Zhongshan City.

**Treatment**

Docetaxel at a dose of 75 mg/m² was infused during a 1-hour on day 1. Based on the recently published Phase I/II studies, nedaplatin was administered intravenously during a 2-hour infusion on day 1 (after the docetaxel infusion) at a dose of 80 mg/m². 12–14 Prior to docetaxel administration, a serotonin antagonist was routinely used to prevent emesis. This regimen was repeated every 3 weeks. In responders, chemotherapy was repeated for a maximum of six cycles. The treatment was discontinued when there were unacceptable adverse reactions, evidence of disease progression at any time, patients’ voluntary withdrawal, or after six cycles of chemotherapy.

**Evaluation of efficacy**

The primary objective was response rate (RR), and secondary objectives were toxicity, time to progression (TTP), and overall survival (OS). Tumor response was evaluated every two cycles during the chemotherapy and then every 3 months after the completion of the chemotherapy using RECIST.

**Evaluation of safety and dose modification**

Toxicities were assessed using National Cancer Institute Common Toxicity Criteria (version 3.0) before each treatment cycle. Complete physical examination, serum chemistry analysis, chest X-ray, and a computed tomography scan of target sites were performed before the start of this study. Before each treatment cycle, the patients were required to have a neutrophil count ≥1,500/µL, a platelet count ≥100,000/µL, adequate hepatic function, and renal function. If the chemotherapy was interrupted by more than 3 weeks, the patients were taken off from the study.

In case of toxicities with grade 3 intensity or higher, the dose was modified according to the following criteria: the dose of docetaxel and nedaplatin for the subsequent cycle was reduced by 20% in the case of a repeated any grade 3 toxicity, and reduced by 40% in the case of a repeated any grade 4 toxicity. If a dose reduction exceeding 40% was required, the patients were excluded from the study. The use of growth factor was permitted.

**Statistical analysis**

This trial was proposed according to Simon’s 15 two-stage Phase II optimal trial design. Based on a hypothesis that a RR of 40% was expected to detect when compared with a minimal, clinically meaningful RR of 20%, the total sample size of 48 patients was necessary. All recruited patients were included in the intention-to-treat analysis of efficacy and toxicity. The overall RR was calculated with 95% confidence intervals (CIs). The TTP and OS were estimated by the Kaplan–Meier method. The TTP was measured from the date of entry into the study until the date of progression, and the OS was calculated from the date of entry to the date of the last follow-up or death. The statistical analyses were performed using an SPSS software package (SPSS 16.0, SPSS Inc., Chicago, IL, USA).

**Results**

**Patient characteristics**

From January 2010 to November 2013, 78 patients were recruited in this trial from The Fifth Affiliated Hospital of Sun Yat-sen University, Cancer Center of Sun Yat-sen
Phase II trial of docetaxel combined with nedaplatin

University, and the People’s Hospital of Zhongshan City. The characteristics of the patients are summarized in Table 1.

### Table 1 Patients characteristics

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Number of patients (n=78)</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>Median 47 (range, 31–68)</td>
<td></td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>29</td>
<td>37.2</td>
</tr>
<tr>
<td>Male</td>
<td>49</td>
<td>62.8</td>
</tr>
<tr>
<td>ECOG performance status</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>21</td>
<td>26.9</td>
</tr>
<tr>
<td>1</td>
<td>45</td>
<td>57.7</td>
</tr>
<tr>
<td>2</td>
<td>12</td>
<td>15.4</td>
</tr>
<tr>
<td>WHO histology type</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Type III</td>
<td>78</td>
<td>100</td>
</tr>
<tr>
<td>Tumor-involved site</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nasopharyngeal</td>
<td>4</td>
<td>5.1</td>
</tr>
<tr>
<td>Lymph node</td>
<td>10</td>
<td>12.8</td>
</tr>
<tr>
<td>Lungs</td>
<td>42</td>
<td>53.8</td>
</tr>
<tr>
<td>Liver</td>
<td>31</td>
<td>39.7</td>
</tr>
<tr>
<td>Bone</td>
<td>9</td>
<td>11.5</td>
</tr>
<tr>
<td>Relapse pattern</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Recurrent</td>
<td>6</td>
<td>7.7</td>
</tr>
<tr>
<td>Metastatic</td>
<td>64</td>
<td>82.0</td>
</tr>
<tr>
<td>Recurrent and metastatic</td>
<td>8</td>
<td>10.3</td>
</tr>
<tr>
<td>Number of involved site</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>53</td>
<td>67.9</td>
</tr>
<tr>
<td>2</td>
<td>19</td>
<td>24.4</td>
</tr>
<tr>
<td>3</td>
<td>6</td>
<td>7.7</td>
</tr>
<tr>
<td>Initial received treatment (cases)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Treatment-naive</td>
<td>12</td>
<td>15.4</td>
</tr>
<tr>
<td>Radiation</td>
<td>66</td>
<td>84.6</td>
</tr>
<tr>
<td>Induction/concurrent/adjuvant chemotherapy</td>
<td>38</td>
<td>48.7</td>
</tr>
</tbody>
</table>

**Abbreviations:** ECOG, Eastern Cooperative Oncology Group; WHO, World Health Organization.

Response and survival

Among 78 patients, only 73 (93.6%) were assessable for response. Three patients were lost to follow-up after the second cycle of the treatment, and two patients withdrew their consents because of toxicities after one cycle. All efficacy data are reported using the intention-to-treat principle. Among the treated patients, 5 patients (6.8%) had complete response (CR), 43 patients (58.9%) had partial responses (PR), 22 patients (30.1%) had stable disease, and three patients (4.1%) had progressive disease. The overall RR (CR + PR) was 65.8% (95% CI, 48.7%–81.2%). With a median follow-up time of 18.6 months (range 2.5–43 months), median TTP was 7.9 months (95% CI, 4.2–10.8 months; Figure 1), median OS for all the patients was 15.7 months (95% CI, 11.6–18.5 months; Figure 2), with a 1-year survival rate of 69% and 2-year survival rate of 33%. Three patients with multiple metastases, who were treated with docetaxel plus nedaplatin regimen, survived more than 38 months and are still alive.

Toxicity

A total of 318 cycles of docetaxel plus nedaplatin were delivered to the 78 patients who were assessable for safety, with the median number of four cycles (range, 1–6 cycles) administered per patient. Dose reduction was needed in ten cycles (of 318) and cycle’s delay was needed in 14 cycles (of 318). The toxicity frequencies are listed in Table 2. The main hematological toxicity was neutropenia with 12 patients (15.4%) experiencing grade 3/4 neutropenia. Only three patients (3.8%) developed febrile neutropenia. Six patients (7.7%) experienced grade 3 anemia and no grade 3/4 thrombocytopenia were observed. The main
non-hematological toxicities were nausea (82%) and vomiting (70.5%). No grade 3/4 nausea and vomiting were observed. Hepatic, renal, neuropathy, fatigue, and other toxicities were mild.

**Discussion**

Chemotherapy has played an important palliative treatment role for recurrent and/or metastatic NPC. However, no standard chemotherapy regimen for advanced NPC has been established. A lot of chemotherapy regimens have been investigated in an attempt to prolong survival and improve the quality of life. The cisplatin-containing regimens are commonly considered the “gold standard”. The doublet combination of cisplatin with 5-FU, capecitabine, taxane, or gemcitabine were commonly employed as first-line chemotherapy regimen.

Despite the well-documented sensitivity of NPC to a variety of cisplatin-containing regimens, treatment with cisplatin can induce severe toxicity including severe GI toxicity, neurologic toxicity, and myelosuppression.

Docetaxel is active against several solid tumors including head and neck cancers. Its activity in NPC has been investigated as a single drug or in combination with platinum in both the metastatic/recurrent and locoregionally advanced settings. Ngeow et al confirmed the single-agent activity of docetaxel in the setting of heavily pretreated metastatic NPC. The median progression free survival of 5.8 months and OS of 12.8 months are encouraging. Nedaplatin is a second-generation platinum complex with lower renal and GI toxicities than cisplatin. In contrast to cisplatin, nedaplatin does not require a large amount of fluid infusion. Moreover, it was reported that nedaplatin is at least as effective as cisplatin for head and neck cancer. So, a combination of docetaxel and nedaplatin to treat NPC seemed to be very rational.

In our current study, this regimen showed a RR of 65.8% with the median TTP of 7.9 months and median OS of 15.7 months, and 1-year survival rate were 69%. In contrast to other clinical trials, the combination of docetaxel and nedaplatin seems to be an effective regimen as first-line chemotherapy for patients with recurrent and metastatic NPC. Chua et al reported a Phase II study in which the patients with metastatic NPC received docetaxel and cisplatin in a 3-week cycle. The overall RR was 62.5% with a median TTP of 5.6 months and median OS of 12.4 months. Ngan et al reported a Phase II trial using gemcitabine plus cisplatin for the treatment of recurrent or metastatic NPC. There were nine CRs and 23 PRs in 44 patients, achieving an overall RR of 73%. With a median follow-up of 17.2 months, 62% survived 1 year, while 36% were alive and progression free. In a study treating patients with metastatic NPC with capecitabine and cisplatin, Li et al reported similar survival data (an overall RR of 36%, a median progression free survival of 5.6 months, and a median OS of 11.9 months). From our current study results, whether docetaxel in combination with nedaplatin is indeed comparable or superior to other regimens as a first-line treatment in terms of efficacy has not yet been fully demonstrated and requires further prospective randomized study.

Compared with cisplatin-based regimens, docetaxel plus nedaplatin regimen showed lower GI toxicities and did not require a large amount of fluid infusion. The main hematological toxicity was neutropenia with 12 patients (15.4%) experiencing grade 3/4 neutropenia. Only three patients (3.8%) developed febrile neutropenia. Six patients (7.7%) experienced grade 3 anemia and no grade 3/4 thrombocytopenia were observed. The main non-hematological toxicities were nausea (82%) and vomiting (70.5%). No grade 3/4 nausea and vomiting were observed. Hepatic, renal, neuropathy, fatigue, and other toxicities were mild. These toxicities were well tolerated. Only two patients were discontinued from the study due to toxic effects. No treatment-related death occurred during this study. However, in a Phase II study treating patients with metastatic NPC with docetaxel and cisplatin reported by Chua et al, treatment-related adverse events seemed to be severe, hematological toxicity with grade 4 neutropenia occurred in 78.9% patients.

**Conclusion**

In summary, our results indicate that the combination of docetaxel and nedaplatin is a useful and well-tolerated treatment as first-line chemotherapy for recurrent and metastatic NPC. Because of the relatively mild toxicity, this combination chemotherapy seemed to be much more patient-friendly comparing with other cisplatin-containing regimens. However, as data with a Phase II study is limited,
further prospective randomized trials are needed to assess the efficacy of docetaxel and nedaplatin to compare it with other cisplatin-based chemotherapy regimens in recurrent and metastatic NPC.

Disclosure
The authors report no conflicts of interest in this work.

References